Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Islasertib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thryv Therapeutics Gets Positive Results in Long QT Syndrome Study
Details : LQT-1213 (islasertib), a potent and selective serum glucocorticoid inducible kinase 1 inhibitor being investigated for the treatment of congenital Long QT Syndrome (cLQTS) Types 2 and 3.
Product Name : LQT-1213
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Islasertib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thryv Receives FDA Orphan Designation for LQT-1213 in Long QT Syndrome
Details : LQT-1213 is a novel, first-in-class SGK1 inhibitor that the USFDA granted Orphan Drug Designation for the treatment of Long QT Syndrome.
Product Name : LQT-1213
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2024
Lead Product(s) : Islasertib,Dofetilide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Islasertib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Investissement Québec
Deal Size : $5.0 million
Deal Type : Financing
Details : The proceeds will be used to immediately accelerate Thryv's portfolio programs including, LQT-1213 (islasertib), a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase (SGK1), being developed for the treatment of Long QT Syndrome and A...
Product Name : LQT-1213
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Islasertib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Investissement Québec
Deal Size : $5.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Thryv’s Serum and Glucocorticoid Regulated Kinase-1 inhibitors significantly reduced the cardiac action potential duration in re-engineered heart cells derived from patients with the major forms of Congenital Long QT syndrome and in a model of Drug Ind...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable